Quantcast

Latest Dendreon Stories

2014-09-11 08:27:28

-Conference Call and Webcast on September 12, 2014 at 8:30 a.m. ET, 5:30 a.m. PT- MENLO PARK, Calif. and LONDON, Sept. 11, 2014 /PRNewswire/ -- CANCER RESEARCH UK and Cancer Research Technology (CRT), the charity's development and commercialisation arm, have reached an agreement with Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a biotechnology company in the emerging field of regenerative medicine, to take forward Asterias' novel immunotherapy treatment AST-VAC2 into clinical trials in...

2014-06-05 16:28:59

Eighty-four percent of shareholder votes cast support annual election of board members. DETROIT, June 5, 2014 /PRNewswire/ -- Eighty-four percent (84%) of votes cast by shareholders at Dendreon voted in favor of a proxy proposal calling for annual election of board members, a strategy - which if enacted - would increase board independence and accountability. Dendreon is a biotechnology company that develops Provenge, an immunotherapy for prostate cancer. The shareholder proposal was...

2014-06-03 12:39:42

LONDON, June 3, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:The Prostate Cancer Therapeutics Market 2013-2023http://www.reportbuyer.com/pharma_healthcare/treatments/prostate_cancer_therapeutics_market_2013_2023.html Report DetailsProstate cancer therapeutics - assess products, developments, and revenue prospectsHow are the leading segments in the prostate cancer therapeutics market performing? Visiongain's new report shows you their prospects to 2023....

2014-04-28 08:31:24

DUBLIN, Apr. 28, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/85rshn/global) has announced the addition of the "Global Therapeutic Vaccines Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 A therapeutic vaccine is a biological combination developed to improve immunity by inducing an attack against a diseased cell or tissue. This differs from prophylactic vaccines, which are administered to an individual...

2014-04-24 08:33:57

Leading Cancer Immunotherapy Startup also Bolsters Leadership Team with Two Key Appointments SEATTLE, April 24, 2014 /PRNewswire-USNewswire/ -- Juno Therapeutics, a biotechnology company focused on bringing forward novel immunotherapies for cancer, today announced the close of its Series A round with $176M in fully committed funds. http://photos.prnewswire.com/prnvar/20140113/DC45426LOGO Juno's initial funding of $120 million came predominantly from leading technology venture...

2014-04-23 16:29:46

MARINA DEL REY, Calif., April 23, 2014 /PRNewswire/ -- Join Prostate Oncology Specialists for an educational talk about PROVENGE - a treatment to stimulate the immune system for advanced prostate cancer. Prostate cancer specialist, Dr. Jeffrey Turner, presents and reviews key topics: Why PROVENGE might be right for me? How do I know the PROVENGE treatment is working?How is PROVENGE different from hormone or chemotherapy?Does PROVENGE affect my PSA?How does PROVENGE boost my immune...

2014-02-20 08:31:11

LONDON, Feb. 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019 Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019 Summary GBI Research has released the pharmaceutical report "Prostate Cancer Therapeutics Market to 2019 - Rising...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.